AbbVie Inc. (ABBV)
Here's Why AbbVie (ABBV) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
AbbVie ABBV announced encouraging fourth-quarter and full-year 2025 results earlier this month that beat expectations. A major portion of the company's top-line growth came from its newer immunology medicines, Rinvoq and Skyrizi, which not only mitigated the impact of continued erosion in legacy drug Humira but also reaffirmed their role as AbbVie's key growth drivers.
The Zacks Analyst Blog AbbVie, RTX, International Business Machines, EVI Industries, and Rocky Mountain Chocolate Factory
AbbVie, RTX and IBM headline Zacks??? top analyst picks after strong earnings beats and solid backlog, cloud and AI-driven momentum.
AbbVie Down Since Q4 Earnings Report: How to Play the Stock
ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.
AbbVie: Dominating Immunology While Building Oncology Upside
None of the Big Pharma players has succeeded in challenging AbbVie's dominance in the immune-mediated inflammatory diseases market. In my view, this is directly related to the near-perfect complementarity of Rinvoq and Skyrizi, spanning indications, routes of administration, and mechanisms of action. The total net revenues of this 'duo' were about $25.87 billion in 2025, up 46.2% from 2024.
Why AbbVie (ABBV) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Dividend Stocks to Hold for the Next 20 Years
AbbVie has demonstrated its ability to successfully navigate change. Coca-Cola will likely soon increase its dividend for the 64th consecutive year.
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'
My top-down strategy targets 'mission-critical' sectors where capital is forced by secular and cyclical tailwinds—data centers, energy, AI, defense, and infrastructure. AI-driven data center and energy spending, defense modernization, and industrial reshoring are creating robust, non-cyclical investment opportunities across select equities. I highlight actionable picks in each segment, including VRT, VST, QXO, MU, TMO, RTX, RACE, MA, CAT, FCX, and key midstream energy names.
AbbVie sues US health agency over Botox price controls
AbbVie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare & Medicaid Services to impose price controls for Botox.
